CASE DISCUSSION

Ventilator-Associated Pneumonia

Presented from India by Dr. V Rakesh

Likes

2560

Views

102

Bookmarks

Case Description

Ventilator-associated pneumonia (VAP) is a serious and potentially life-threatening infection that occurs in individuals who are on mechanical ventilation in hospitals. Patients on ventilators are often at an increased risk due to the invasive nature of the equipment and compromised respiratory...

Case Summary

Ventilator-associated pneumonia (VAP) is defined as pneumonia that develops in patients more than 48 hours after mechanical ventilation. It is a significant concern in ICUs, being the most common nocosomial infection in ventilated patients. The incidence ranges from 9 to 28%, with mortality rates varying from 27 to 76%. VAP increases ICU stay by approximately 4 days and can increase mortality by 2 to 10 fold, especially in early stages.

Speaker Profile

Dr. V Rakesh

HOD, Critical Care and ECMO Specialist, Gemcare Hospitals, Hyderabad"

Dr. V. Rakesh is a skilled intensivist and ECMO specialist currently working in Gemcare Hospitals. He is Also the CEO of Varahi Care Services which is a specialized firm offering online service for second opinions on critical care services. He has demonstrated a history of providing exceptional patient care in fast-paced critical environments. Rakesh's expertise includes critical care, advanced hemodynamic monitoring, and thoracic organ transplant anesthesia. He serves as a team lead for a 6-bedded CLOSED ECMO ICU, showcasing his leadership abilities. Rakesh is an expert in air transport for critically ill patients and is dedicated to teaching students at various levels. He is recognized for his contributions to medical science, holding two patents, and has received an honorary fellowship from the KALAM INSTITUTE OF HEALTH TECHNOLOGY. His achievements extend to being a national and international level faculty in ECMO training programs and serving as the committee head for research, data, and guidelines for ECMO in India.

Disclosures

Assimilate requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships for anyone with the ability to control the content of this educational activity have been reviewed and mitigated. Others involved in the planning of this activity have no relevant financial relationships.